Androgen deprivation therapy and side effects: are GnRH antagonists safer?
Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and antagonists is the mainstay of advanced prostate cancer treatment. Both drug classes decrease levels of luteinizing hormone and follicle-stimulating hormones (FSH), thereby lowering testosterone to castrate le...
Main Authors: | Stephen J Freedland, Per-Anders Abrahamsson |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Asian Journal of Andrology |
Subjects: | |
Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2021;volume=23;issue=1;spage=3;epage=10;aulast=Freedland |
Similar Items
-
Recent Development of Non-Peptide GnRH Antagonists
by: Feng-Ling Tukun, et al.
Published: (2017-12-01) -
Microdose GnRH Agonist Flare-Up versus Ultrashort GnRH Agonist Combined with Fixed GnRH Antagonist in Poor Responders of Assisted Reproductive Techniques Cycles
by: Maryam Eftekhar, et al.
Published: (2013-01-01) -
GnRH Antagonists Produce Differential Modulation of the Signaling Pathways Mediated by GnRH Receptors
by: Samantha Sperduti, et al.
Published: (2019-11-01) -
Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer
by: Mahnaz Roayaei, et al.
Published: (2013-01-01) -
Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
by: Per-Anders Abrahamsson
Published: (2017-10-01)